Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer

Lord, Simon R., Cheng, Wei-Chen, Liu, Dan, Gaude, Edoardo, Haider, Syed, Metcalf, Tom, Patel, Neel, Teoh, Eugene J., Gleeson, Fergus, Bradley, Kevin ORCID:, Wigfield, Simon, Zois, Christos, McGowan, Daniel R., Ah-See, Mei-Lin, Thompson, Alastair M., Sharma, Anand, Bidaut, Luc, Pollak, Michael, Roy, Pankaj G., Karpe, Fredrik, James, Tim, English, Ruth, Adams, Rosie F., Campo, Leticia, Ayers, Lisa, Snell, Cameron, Roxanis, Ioannis, Frezza, Christian, Fenwick, John D., Buffa, Francesca M. and Harris, Adrian L. 2018. Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer. Cell Metabolism 28 (5) , pp. 679-688. 10.1016/j.cmet.2018.08.021

[thumbnail of PIIS1550413118305229.pdf] PDF - Published Version
Available under License Creative Commons Attribution.

Download (4MB)


Late-phase clinical trials investigating metformin as a cancer therapy are underway. However, there remains controversy as to the mode of action of metformin in tumors at clinical doses. We conducted a clinical study integrating measurement of markers of systemic metabolism, dynamic FDG-PET-CT, transcriptomics, and metabolomics at paired time points to profile the bioactivity of metformin in primary breast cancer. We show metformin reduces the levels of mitochondrial metabolites, activates multiple mitochondrial metabolic pathways, and increases 18-FDG flux in tumors. Two tumor groups are identified with distinct metabolic responses, an OXPHOS transcriptional response (OTR) group for which there is an increase in OXPHOS gene transcription and an FDG response group with increased 18-FDG uptake. Increase in proliferation, as measured by a validated proliferation signature, suggested that patients in the OTR group were resistant to metformin treatment. We conclude that mitochondrial response to metformin in primary breast cancer may define anti-tumor effect.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: Elsevier
ISSN: 1550-4131
Date of First Compliant Deposit: 1 June 2020
Date of Acceptance: 24 August 2018
Last Modified: 07 Nov 2022 10:21

Citation Data

Cited 70 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics